Literature DB >> 15827164

Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A.

Cary A Moody1, Rona S Scott, Nazanin Amirghahari, Cherie-Ann Nathan, Lawrence S Young, Chris W Dawson, John W Sixbey.   

Abstract

Control of translation initiation is one means by which cells regulate growth and proliferation, with components of the protein-synthesizing machinery having oncogenic potential. Expression of latency protein LMP2A by the human tumor virus Epstein-Barr virus (EBV) activates phosphatidylinositol 3-kinase/Akt located upstream of an essential mediator of growth signals, mTOR (mammalian target of rapamycin). We show that mTOR is activated by expression of LMP2A in carcinoma cells, leading to wortmannin- and rapamycin-sensitive inhibition of the negative regulator of translation, eukaryotic initiation factor 4E-binding protein 1, and increased c-Myc protein translation. Intervention by this DNA tumor virus in cellular translational controls is likely to be an integral component of EBV tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827164      PMCID: PMC1082717          DOI: 10.1128/JVI.79.9.5499-5506.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction.

Authors:  S Fruehling; S K Lee; R Herrold; B Frech; G Laux; E Kremmer; F A Grässer; R Longnecker
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

2.  The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth.

Authors:  D Rousseau; A C Gingras; A Pause; N Sonenberg
Journal:  Oncogene       Date:  1996-12-05       Impact factor: 9.867

3.  Two related Epstein-Barr virus membrane proteins are encoded by separate genes.

Authors:  J Sample; D Liebowitz; E Kieff
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

4.  Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k.

Authors:  H B Jefferies; S Fumagalli; P B Dennis; C Reinhard; R B Pearson; G Thomas
Journal:  EMBO J       Date:  1997-06-16       Impact factor: 11.598

5.  Mechanism of activation of protein kinase B by insulin and IGF-1.

Authors:  D R Alessi; M Andjelkovic; B Caudwell; P Cron; N Morrice; P Cohen; B A Hemmings
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

6.  Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma.

Authors:  A Neri; F Barriga; G Inghirami; D M Knowles; J Neequaye; I T Magrath; R Dalla-Favera
Journal:  Blood       Date:  1991-03-01       Impact factor: 22.113

7.  Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E.

Authors:  D Rousseau; R Kaspar; I Rosenwald; L Gehrke; N Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 11.205

8.  Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma.

Authors:  R Pathmanathan; U Prasad; R Sadler; K Flynn; N Raab-Traub
Journal:  N Engl J Med       Date:  1995-09-14       Impact factor: 91.245

9.  A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome.

Authors:  G Laux; M Perricaudet; P J Farrell
Journal:  EMBO J       Date:  1988-03       Impact factor: 11.598

10.  The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain.

Authors:  R B Pearson; P B Dennis; J W Han; N A Williamson; S C Kozma; R E Wettenhall; G Thomas
Journal:  EMBO J       Date:  1995-11-01       Impact factor: 11.598

View more
  60 in total

1.  An orthotopic model of metastatic nasopharyngeal carcinoma and its application in elucidating a therapeutic target that inhibits metastasis.

Authors:  Pamela A Smith; David Merritt; Leah Barr; David A Thorley-Lawson
Journal:  Genes Cancer       Date:  2011-11

Review 2.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

3.  Herpes Simplex Virus is Akt-ing in translational control.

Authors:  Kara L Norman; Peter Sarnow
Journal:  Genes Dev       Date:  2010-12-01       Impact factor: 11.361

4.  Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.

Authors:  Osman Cen; Richard Longnecker
Journal:  Mol Cancer Ther       Date:  2011-01-31       Impact factor: 6.261

Review 5.  Microbiome and malignancy.

Authors:  Claudia S Plottel; Martin J Blaser
Journal:  Cell Host Microbe       Date:  2011-10-20       Impact factor: 21.023

Review 6.  The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  Chi Man Tsang; Sai Wah Tsao
Journal:  Virol Sin       Date:  2015-04-21       Impact factor: 4.327

7.  Augmented latent membrane protein 1 expression from Epstein-Barr virus episomes with minimal terminal repeats.

Authors:  Allison M Repic; Mingxia Shi; Rona S Scott; John W Sixbey
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

Review 8.  Modulation of the Translational Landscape During Herpesvirus Infection.

Authors:  Britt A Glaunsinger
Journal:  Annu Rev Virol       Date:  2015-07-02       Impact factor: 10.431

9.  Activation of mTORC1 signaling pathway in AIDS-related lymphomas.

Authors:  Mouna El-Salem; Puthiyaveettil N Raghunath; Michal Marzec; Xiaobin Liu; Monika Kasprzycka; Erle Robertson; Mariusz A Wasik
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

10.  PI3K signaling regulates rapamycin-insensitive translation initiation complex formation in vaccinia virus-infected cells.

Authors:  Izabela Zaborowska; Derek Walsh
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.